Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention — Stella

Home/Pediatric HIV Infection/Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention

View on ClinicalTrials.gov

Recruiting

Back to Pediatric HIV Infection trials

Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Nigeria

University College Hospital, Ibadan, Oyo State

Key details

Phase

Early testing

Sponsor

Brigham and Women's Hospital

Collaborators

APIN Public Health Initiatives, University of Cape Town

Enrollment target

~25 participants

Started

November 2024

Primary completion

February 2027

Age range

4 Weeks – 11 Years

Last updated December 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.